Qingchun Jin

机构：Dana-Farber Cancer Institute · ORCID：0000-0001-6388-5123

发表论文 129 篇 · 总被引 817 次 · h-index 12

代表论文

• HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort (2025 · Journal of Hepatology · 被引 7)
• Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials (2024 · Clinical Breast Cancer · 被引 6)
• Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial (2025 · Annals of Surgical Oncology · 被引 5)
• Abstract PS18-06: Primary results and the transcriptomic analysis of PELOPS, a randomized phase II study of neoadjuvant palbociclib with or without endocrine therapy for breast cancer patients with invasive lobular carcinoma or invasive ductal carcinoma (2025 · Clinical Cancer Research · 被引 3)
• Validation of longitudinal biomarker screening algorithms for HCC detection in patients with cirrhosis (2026 · Hepatology Communications · 被引 2)
• Abstract PS2-07-06: Prevalence and dynamics of circulating tumor DNA among patients with triple-negative breast cancer undergoing preoperative systemic therapy with or without immunotherapy (2026 · Clinical Cancer Research · 被引 1)